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Cell surface proteolysis has emerged as an important mecha-
nism for the generation of biologically active proteins that mediate
a diverse range of cellular functions. The proteolytic activities of
membrane-anchored proteins, such as ADAMs1 (1) and MT-MMPs
(2), are thought to play central roles in cell surface-activating
events. In contrast, most of the members of the serine protease
family, one of the oldest characterized and largest multigene pro-
teolytic families, are either secreted enzymes or sequestered in
cytoplasmic storage organelles awaiting signal-regulated release.
These serine proteases have well characterized roles in diverse
cellular activities, including blood coagulation, wound healing, di-
gestion, and immune responses, as well as tumor invasion and
metastasis. However, during the last few years there has been an
explosion in the identification of transmembrane proteins contain-
ing C-terminal extracellular serine protease domains. These en-
zymes are ideally positioned to interact with other proteins on the
cell surface as well as soluble proteins, matrix components, and
proteins on adjacent cells. In addition, these membrane-spanning
proteases have cytoplasmic N-terminal domains, suggesting possi-
ble functions in intracellular signal transduction. This review de-
lineates for the first time this emerging class of cell surface pro-
teolytic enzymes, the type II transmembrane serine proteases
(TTSPs), to highlight their structural features, expression profiles,
and possible roles in mediating cell surface proteolytic events.
Structural Features of TTSPs
In mammals the TTSPs currently consist of 17 members (Table
I), of which seven are found in man. Enteropeptidase (also known
as enterokinase) (3), because of its essential role in the processing
of digestive proteases, was the first member of this group to be
discovered nearly a century ago. The other more recently identified
members include hepsin (4), human airway trypsin-like protease
(HAT) (5), corin (6), MT-SP1 (7) (also known as matriptase (8)),
TMPRSS2 (9), and most recently TMPRSS42 (10). The only non-
mammalian TTSP identified to date is the Drosophila protease
stubble-stubbloid (st-sb) (11). Mammalian orthologues have been
reported for enteropeptidase (mouse (12), rat (13), cow (14), and pig
(15)), hepsin (mouse (16) and rat (17)), corin (mouse, also known as
LRP4 (18)), MT-SP1 (mouse, also known as epithin (19)), and
TMPRSS2 (mouse, also known as epitheliasin (20)) (Table I). The
TTSPs share a number of common structural features including (i)
a proteolytic domain, (ii) a transmembrane domain, (iii) a short
cytoplasmic domain, and (iv) a variable length stem region contain-
ing modular structural domains, which links the transmembrane
and catalytic domains (Fig. 1). It is this unique combination of
domains that suggests novel roles for the TTSPs at the cell surface.
Proteolytic Domains—As is the case for the wider family of
enzymes of the chymotrypsin (S1) fold,3 the proteolytic domains of
the TTSPs share a high degree of amino acid sequence identity. In
particular, the histidine, aspartate, and serine residues necessary
for catalytic activity are present in highly conserved motifs. TTSPs
are synthesized as single chain zymogens and are likely activated
by cleavage following an arginine or lysine present in a highly
conserved activation motif. Based on the predicted presence of a
conserved disulfide bond linking the pro- and catalytic domains
(Fig. 1), the TTSPs are likely to remain membrane-bound following
activation. However, the isolation of soluble forms of enteropepti-
dase (21, 22), HAT (23), and MT-SP1 (24) suggests that the extra-
cellular domains of at least some of the TTSPs may also be shed
from the cell surface. Other cysteine residues conserved among the
TTSPs include six cysteines predicted to form three intraprotease
domain disulfide bonds. Enteropeptidase and hepsin each have one
and corin has two additional predicted disulfide linkages within the
catalytic domain. The presence of an aspartate six residues before
the catalytic serine, which in the activated TTSP would be posi-
tioned at the bottom of the S1 substrate binding pocket, is indica-
tive that all of the TTSPs have preference for substrates containing
an arginine or lysine in the P1 amino acid position (S1 and P1
designations are described (25)). The cleavage specificities and
candidate physiological substrates for some of the TTSPs have been
elucidated. The predicted cleavage specificity following basic amino
acids indicates that the TTSPs are likely to have a degree of
autocatalytic activity. Indeed truncated mouse hepsin lacking cy-
toplasmic and transmembrane domains (16) and the human MT-
SP1 proteolytic domain (7) are capable of autoactivation. In con-
trast, bovine enteropeptidase has extremely low autocatalytic
activity (26). Interestingly, the proteolytic domain of bovine en-
teropeptidase has an additional role in the targeting of enteropep-
tidase to the apical membrane of enterocytes (27).
Transmembrane Domains—Each of the TTSPs contains a hydro-
phobic domain near the N terminus. This domain is predicted to
span the plasma membrane in such a way that the proteolytic
domain lies extracellularly, presumably to localize TTSP proteo-
lytic activity in close proximity to target substrates and/or to per-
mit regulated release of the protein from the cell surface. Cell
surface localization has been experimentally demonstrated for en-
teropeptidase, hepsin (28, 29), MT-SP1 (30, 31), TMPRSS2 (20),
and TMPRSS3 (10).
Cytoplasmic Domains—The cytoplasmic domains of the TTSPs
(Fig. 1) range in length from 12 amino acids for HAT to 112 amino
acids for murine corin. Whether these domains have the potential
to support interactions with cytoskeletal components and signaling
molecules is not yet known. However, a number of the TTSPs
including corin, MT-SP1, st-sb, and TMPRSS2 contain consensus
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phosphorylation sites for either or both of protein kinase C and
casein kinase II. In addition, based on the cellular sorting of other
integral membrane proteins (32) it is likely that the cytoplasmic
and transmembrane domains also contribute to the targeting of the
TTSPs to a particular cell surface in polarized cells.
Stem Regions—The stem regions of the TTSPs contain as many as
11 structural domains that may serve as regulatory and/or binding
domains (Fig. 1). These include low density lipoprotein (LDL) recep-
tor class A domains, Group A scavenger receptor (SR) domains,
frizzled domains, Cls/Clr, urchin embryonic growth factor and bone
morphogenic protein 1 (CUB) domains, sea urchin sperm protein,
enterokinase, agrin (SEA) domains, a meprin, A5 antigen, and recep-
tor protein phosphatase m (MAM) domain, and a disulfide knotted
domain. Hepsin is the only TTSP that does not possess an identified
structural domain within its stem region. Although functional roles
for individual stem region domains have not been demonstrated, the
stem region of bovine enteropeptidase has been shown to be required
for efficient cleavage of its physiological substrate trypsinogen (26).
In addition, the N terminus of the stem region of this protein is
required for delivery of enteropeptidase to the apical surface of po-
larized Madin-Darby canine kidney cells (27).
The most common stem region structural domain is the LDL
receptor class A domain: corin contains eight, MT-SP1 four, en-
teropeptidase two, and TMPRSS2 and TMPRSS4 one each (Fig. 1).
Although the function of these domains in the TTSPs has not been
demonstrated, in other proteins they bind Ca21 ions and mediate the
internalization of macromolecules including serine proteasezinhibitor
complexes and lipoproteins (33–35). In addition, although LDL re-
ceptor domains also function in the uptake of LDLs, increased LDL
uptake could not be demonstrated following expression of murine
corin in COS cells (18).
Six other structural domains that are thought to be involved in
protein-protein interactions or protein-ligand interactions are
found in various TTSPs. SR domains (36) are present in corin,
enteropeptidase, TMPRSS2, and TMPRSS3; frizzled domains (37)
are present in corin; CUB domains (38) are present in enteropep-
tidase and MT-SP1; SEA domains (39) are present in HAT and
enteropeptidase; a MAM domain (40) is present in enteropeptidase;
and a disulfide knotted domain (41) is present in st-sb (Fig. 1). In
addition to these structural domains, human and mouse MT-SP1s
possess a conserved RGD motif (42) present in the first CUB
domain. Interestingly, truncated human MT-SP1 lacking cytoplas-
mic and transmembrane domains remains bound to the cell surface
of COS cells (31). Binding may be mediated via an interaction
between the MT-SP1 RGD motif and an integrin protein or another
cell surface protein. Alternatively, the mode of attachment could be
via a direct link such as a hydrocarbon chain.
Tissue Expression of TTSPs
Although a few of the TTSPs are expressed across several tissue
and cell types, in general these enzymes demonstrate relatively
restricted expression patterns, indicating that they may have tis-
sue-specific functions (Table I). Enteropeptidase shows a very nar-
row expression pattern, being restricted in normal tissues to en-
terocytes of the proximal small intestine (12). Corin expression is
also quite specific, with corin mRNA highly expressed in human
heart (6) and corin protein expression localized to cardiac myocytes
(43). HAT is predominantly expressed in trachea (5, 23). Human
TMPRSS2 expression is predominantly associated with prostate (9,
44).4 Hepsin, originally identified from liver, is highly expressed in
fetal liver and kidney (45). Hepsin mRNA has been reported to be
overexpressed by ovarian tumors (46), and protein expression has
been localized to tumor cell membranes in renal cell carcinoma
(29). TMPRSS4 has only recently been characterized and was iden-
tified as a consequence of its strong up-regulation in pancreatic
tumors (10). While TMPRSS4 was not detected in normal pancreas,
very low level TMPRSS4 mRNA expression was detected in tissues
of the gastrointestinal tract and in some tissues of the urogenital
tract (10). MT-SP1 was originally identified from a human breast
cancer line (30) but shows the broadest pattern of expression of the
TTSPs being detected in a wide range of both human (7) and
murine tissues (19).
Biochemical Data and Pathophysiological Roles
The majority of the TTSPs have been identified relatively re-
cently and consequently have not been extensively characterized.
Enteropeptidase is somewhat of an exception. Although the enzy-
matic activity ascribed to enteropeptidase was first identified al-
most a century ago (47) it has been only recently that the complete
amino acid sequence was described (3). Enteropeptidase functions
near the apex of the digestive enzymatic cascade activating the
digestive protease trypsinogen to trypsin, which subsequently ac-
tivates other enzymes including chymotrypsinogen, proelastase,
prolipases, and procarboxypeptidases. Enteropeptidase possesses
extremely low autocatalytic activity, and it has been proposed that
the serine protease duodenase, secreted by duodenal epitheliocytes,
may be its physiological activator (48). Active enteropeptidase con-
4 The Northern blot data reported (9) are incorrectly labeled due to inver-
sion of the membranes (Stylianos Antonarakis, personal communication).
TABLE I
Summary of type II transmembrane serine proteases
The abbreviations used are: b, brain; bl, bladder; bp, Drosophila 36-h pupae; c, colon; de, Drosophila 12–18-h embryo; dp, Drosophila early
prepupae; e, esophagus; h, heart; int, intestine; k, kidney; l, lung; le, leukocytes; li, liver; p, pancreas; pl, placenta; pr, prostate; psi, proximal small
intestine (si); s, spleen; st, stomach; t, testes; th, thymus; tr, trachea.
a Splice variants have been identified. b Experimentally derived molecular weight. c V5/His6-tagged protein.
d Putative assignment based on our
unpublished observation that LRP4 sequences have greater than 96% identity with mouse chromosome 5 BAC RP23-294A15 sequences deposited
in the GenBank™ htgs database (GenBank™ accession no. AC036146). e Closest linkage to the Fli1 gene.
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sists of heavy and light chains that are extensively glycosylated
(27, 49). It has recently been reported that physiological concen-
trations of pancreatic trypsin activate protease-activated receptor
(PAR) 2 at the apical membrane of enterocytes (50). PAR2 is a
member of the PAR family of signal-transducing, G protein-cou-
pled, plasma membrane-spanning receptors, which are activated
by the proteolytic action of select serine proteases (51, 52). These
data and the observation that an exosite in the heavy chain of
enteropeptidase is required for efficient recognition of trypsinogen
(26) suggest that enteropeptidase may play a role in facilitating
trypsin-mediated PAR2 activation on enterocytes. Thus enteropep-
tidase may localize trypsinogen/trypsin at the membrane of entero-
cytes, initiating a limited proteolytic cascade at the cell surface in
close proximity to the trypsin cleavage target PAR2, thereby facil-
itating receptor activation and signal transduction.
Hepsin is a glycoprotein originally cloned from human liver and
hepatoma cell lines and, more recently, implicated in mammalian
cell growth and morphology (53), tumor progression (28), and de-
velopmental processes, such as blastocyst hatching (16). The im-
portance of hepsin in vivo, however, remains unclear as homozy-
gous hepsin null mice are phenotypically normal (54). An as yet
unexplained phenotype of the hepsin 2/2 mice is a 2-fold higher
serum concentration of bone-derived alkaline phosphatase com-
pared with wild type mice (55).
The human airway TTSP, HAT, was originally purified as a
soluble protein from the sputum of patients with chronic airway
diseases. Full-length HAT is synthesized, translocated to the cell
surface where it is processed to a soluble form, and then released
from tracheal serous glands as part of the host immune defense
system (5).
Significantly, the human heart TTSP, corin, is an in vitro acti-
vator of pro-atrial natriuretic peptide (ANP), a cardiac hormone
essential for the regulation of blood pressure (56), suggesting that
corin is the long sought pro-ANP convertase. This proteolytic cleav-
age is critical for the regulation of ANP activity (57); thus, corin
may well prove to be an important factor in the regulation of major
cardiovascular diseases. Dysfunctional corin was proposed to be a
candidate for the rare congenital heart disease, total anomalous
pulmonary venous return (TAPVR), as the corin gene colocalizes to
the TAPVR locus on human chromosome 4p12–13 (6). In addition
to heart, murine corin is expressed by chondrocytes in a differen-
tiation stage-specific manner during mouse development, suggest-
ing that this protease may play a role during chondrocyte differ-
entiation/bone formation (6). However, while human and murine
corin share high homology, common structural features, expression
profiles, and syntenic chromosomal locations, these proteases are
variant in the lengths of their cytoplasmic domains (45 residues in
human and 112 in mouse) and show no conservation in amino acid
sequence in this domain. This may indicate that murine and hu-
man corin have different but perhaps overlapping species-specific
roles, or alternatively the cytoplasmic domain is not essential for
corin functions.
In other significant recent experiments it has been shown that
MT-SP1 may be involved in initiating signaling and proteolytic
cascades via the activation of the cell surface-associated proteins
PAR2 and pro-uPA (31). Interestingly, MT-SP1 from breast cancer
cells is detected largely as an uncomplexed protein, whereas in
milk it is present mainly as a complex with the Kunitz-type serine
protease inhibitor hepatocyte growth factor inhibitor-1 (24). It will
be important to identify the inhibitor binding domains of MT-SP1
and the function of the proteasezinhibitor complex.
TMPRSS2 and TMPRSS4 have been identified through associa-
tion with cancer. TMPRSS2 is thought to play a role in epithelial
cell biology, and its association with prostate carcinogenesis has led
to the proposal that it may be a diagnostic or therapeutic target for
prostate cancer (44). TMPRSS2 has been proposed to be part of an
enzymatic cascade involving the serine proteases prostate-specific
antigen and human kallikrein K2 in a manner analogous to the
fibrinolytic and blood coagulation cascades (44). TMPRSS4 is over-
expressed in pancreatic cancers; however, its functional signifi-
cance remains unclear (10).
The Drosophila serine protease st-sb is one of a number of
proteases involved in fly morphogenesis (11) and has a proteolytic
function in detaching imaginal disks from extracellular matrices. In
addition, the phenotype of st-sb mutants has led to speculation that
the encoded protein is involved in outside to inside signal transduc-
tion via its cytoplasmic domain, thus resulting in cytoskeletal reor-
ganization and changes in cell shape during morphogenesis (11).
Analogous Membrane-associated Proteolytic Systems
In contrast to the traditional protein catabolic functions of many
of the secreted members of the serine protease family and based on
the presence of multiple structural domains in the TTSPs, it is
tantalizing to speculate that the TTSPs function as key regulators
of signaling events at the plasma membrane. Precedents for such
functions come from other more well characterized membrane-
associated proteolytic systems such as the ADAMs (1), the MT-
MMPs (2), and the uPAzuPA receptor system (58).
The ADAMs have recognized and proposed roles in the proteol-
ysis of extracellular matrix (ECM) components and cell surface
proteins, in mediating cell adhesion via integrin binding, in cell
fusion and signaling via interactions of their cytoplasmic domains,
and in RGD-mediated interactions with integrins (59–61). The
TTSPs are similarly positioned at the plasma membrane to release
ECM components and to proteolytically activate cell surface proteins
such as PARs, growth factors, and cytokines, and to interact with cell
surface and soluble ligands. In addition, the presence of the cytoplas-
mic domains indicates that the TTSPs may be capable of interacting
with the cytoskeleton and/or with cellular signaling molecules.
The MT-MMPs function in pericellular cascades to activate other
MMPs involved in the cleavage of ECM components. The TTSPs may
well perform similar functions in activating proteolytic cascades on
FIG. 1. Type II transmembrane serine protease domain struc-
ture. Structures, listed by length, are of the seven human TTSPs and
the Drosophila TTSP st-sb. The amino acid (aa) sequence of each
protein was scanned using the ProfileScan algorithm to confirm the
presence of each domain. Numbers delineate the location of each
domain.
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the plasma membrane. Indeed, this function has been demonstrated
for enteropeptidase in the activation of digestive proteases. Moreover,
there is increasing evidence for cross-talk between proteolytic sys-
tems. The uPAzuPA receptor system of cell surface-localized proteo-
lytic activity has a recognized role in the initial stage of MMP acti-
vation (62), and other serine proteases are also capable of in vitro
MMP activation (63, 64). The TTSPs could play a direct role in MMP
activation or an indirect role in localizing and activating other serine
proteases more directly associated with MMP activation. The activa-
tion of uPA by MT-SP1 (31) and subsequent downstream MMP
activation could be an example of such cross-talk.
Several other parallels may also be drawn from the uPAzuPA
receptor system. That the TTSPs are directly anchored to the
plasma membrane implies that they have potential to mimic local-
ization of the uPAzuPAR system to the leading edge of migrating
tumor cells (65). Further, the interaction of the uPAzuPAR system,
via a nonproteolytic mechanism, in mediating cell-cell contacts
through association with integrins may also parallel TTSP proper-
ties. Indeed the multidomain structure of the TTSPs indicates their
capacity to interact with multiple partners and suggests the pos-
sibility that these membrane proteins may form part of a signalo-
some-like complex, thereby mediating at the cell surface multiple
signaling pathways as is the case for the uPAzuPAR system (58).
Concluding Remarks
What is known about the TTSPs is that they function or have the
structural motifs necessary to function as serine proteases. What can
be speculated upon is that their numerous and varied nonproteolytic
domains are likely to mediate interactions with proteolytic substrates
and inhibitors as well as other proteins and ligands. Such interac-
tions will potentially regulate the proteolytic activity of the catalytic
domain but perhaps may also have functions quite independent of
this domain. Furthermore, given the integral plasma membrane
nature of the TTSPs, it is tempting to speculate that at least some of
the TTSPs will function directly in transducing signals across the
plasma membrane, as has been suggested for the Drosophila TTSP
st-sb (11). There is clearly a need for a greater understanding of the
biology and physiological functions of this group of unique proteases
to obtain a better picture of the dynamics occurring on the cell
surface. Because of the mosaic structure of the TTSPs it will be
important to understand the role of their individual domains as well
as the role of each protein in toto.
Note Added in Proof—Two cDNAs encoding the putative TTSPs Xesp-2
and XMT-SP1 have recently been identified from Xenopus laevis (67).
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